The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus
about
Ghrelin.Combination of symptoms, syndrome and disease: treatment of refractory diabetic gastroparesis.Novel therapeutic agents in neurogastroenterology: advances in the past year.Emerging drugs for the treatment of gastroparesis.Drug-drug interactions in pharmacologic management of gastroparesis.Peripheral mechanisms in appetite regulation.Emerging treatments in Neurogastroenterology: relamorelin: a novel gastrocolokinetic synthetic ghrelin agonist.The Pentapeptide RM-131 Promotes Food Intake and Adiposity in Wildtype Mice but Not in Mice Lacking the Ghrelin ReceptorDelayed Gastric Emptying Is Associated With Early and Long-term Hyperglycemia in Type 1 Diabetes Mellitus.Early investigational therapeutics for gastrointestinal motility disorders: from animal studies to Phase II trials.Pharmacological agents currently in clinical trials for disorders in neurogastroenterology.From Belly to Brain: Targeting the Ghrelin Receptor in Appetite and Food Intake Regulation.Future Treatment of Constipation-associated Disorders: Role of Relamorelin and Other Ghrelin Receptor Agonists.Treatment of functional dyspepsia and gastroparesis.Gastric emptying and glycaemia in health and diabetes mellitus.Emerging drugs for functional dyspepsia.Therapeutic applications of ghrelin agonists in the treatment of gastroparesis.Ghrelin and motilin receptors as drug targets for gastrointestinal disorders.Current and Emerging Medical Therapies for Gastroparesis.Gastroparesis: Medical and Therapeutic Advances.Novel Diet, Drugs, and Gastric Interventions for Gastroparesis.Emerging strategies for the treatment of gastroparesis.Newest Drugs for Chronic Unexplained Nausea and Vomiting.Investigational drug therapies for the treatment of gastroparesis.Management of gastroparesis: beyond basics.Relamorelin for the treatment of gastrointestinal motility disorders.Increase in plasma acyl ghrelin levels is associated with abatement of dyspepsia following Helicobacter pylori eradication.Effects of ghrelin receptor agonist, relamorelin, on gastric motor functions and satiation in healthy volunteers.Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study.Relationship Between Gastric Emptying and Diurnal Glycemic Control in Type 1 Diabetes Mellitus: A Randomized Trial.Diabetes and the Small Intestine.Short-Term Effects of Relamorelin on Descending Colon Motility in Chronic Constipation: A Randomized, Controlled Trial.What Has Bariatric Surgery Taught Us About the Role of the Upper Gastrointestinal Tract in the Regulation of Postprandial Glucose Metabolism?Diabetic gastroparesis: current challenges and future prospects
P2860
Q28081062-25F217E6-B4CF-4CAC-B8D9-D2D320CFF7EBQ33887129-F320F774-4A0A-434C-97AB-DE2F5AA026FCQ33934623-97DDA19E-20A0-42F1-8423-54286F7CF7F8Q34412103-3751B200-0B22-4B66-A477-7110AD0807C7Q34480053-A2D073A5-0ECF-447F-9A27-62608CD50703Q35204654-59037B22-54C7-4CA6-965F-D899EF91A7B3Q35584740-82D47572-4A63-4EF4-A1E0-A9D1FB68EEACQ35596484-8D5F03AA-26EA-4A55-A9E5-0FDE3DEE2F00Q35893638-F3682966-4925-4DE5-9DD6-F698885334D2Q36082843-3EC44931-4791-47C6-92E5-D470D48572CCQ37200907-75CEBE3B-36E2-4666-A677-72B01685ABE9Q37690695-0D52720B-CD48-4839-B471-637C319BD7AFQ37740008-2F82B91A-A59B-4769-A313-21B4F9A7E61AQ38244400-A0AD2405-30EF-4B83-996F-02DCB72E9BB6Q38271037-10CF7C5F-D0A8-4E16-B189-9A55FC12E4A5Q38342083-485EC888-D55B-4753-AF4B-E7730E0AB3B6Q38363587-2063613D-1C2B-4452-9787-288D08B51457Q38590705-8B970B2D-3EA9-4758-8A91-7A967DFCA3E8Q38617535-95EF88F9-3D1C-4BB8-9275-F073820287DEQ38672906-09D1DED0-1CCD-4AE7-8710-CB54FF4A8095Q38695314-43921C61-3FCF-420D-A2E1-C2219BFB96EEQ38721476-C0B290A8-9404-49BB-A550-4D75E75B568CQ38977503-A56CD411-8332-4189-A187-CA1E6AF3D230Q39106195-1E10D124-A0A6-4A00-ABD8-D4011ABDC1ABQ39125102-7285B3C1-FE0A-4073-A053-AC252654551DQ39150802-E1645DDA-57EE-463E-BC74-C80811C07618Q40978401-5131D59D-0F97-4EB3-8E85-959D9BED0501Q42721572-4A1E951F-0E47-4A9D-B410-46B14B75442CQ47816254-67D94927-B2E9-4A19-8D0E-8625EF5865E1Q48034787-5D261138-F1EE-4C2B-BF94-E90D1CD3E6FEQ50075045-33D46CD1-A233-42CA-BCF6-F2EA54744C74Q51295486-021DBA00-B739-47FC-BFA3-10E6C53C6B74Q55555487-4E392D23-B370-42B8-BD2D-88282878ECACQ57491893-D3D953A5-C00A-4863-97CD-5FB7E08F9184
P2860
The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 April 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The ghrelin agonist RM-131 acc ...... with type 1 diabetes mellitus
@en
The ghrelin agonist RM-131 acc ...... with type 1 diabetes mellitus.
@nl
type
label
The ghrelin agonist RM-131 acc ...... with type 1 diabetes mellitus
@en
The ghrelin agonist RM-131 acc ...... with type 1 diabetes mellitus.
@nl
prefLabel
The ghrelin agonist RM-131 acc ...... with type 1 diabetes mellitus
@en
The ghrelin agonist RM-131 acc ...... with type 1 diabetes mellitus.
@nl
P2093
P2860
P1476
The ghrelin agonist RM-131 acc ...... with type 1 diabetes mellitus
@en
P2093
Adrian Vella
Andrea Shin
Deborah Rhoten
Duane Burton
Irene Busciglio
Michael Ryks
Steven A Smith
P2860
P304
1453-1459.e4
P356
10.1016/J.CGH.2013.04.019
P407
P577
2013-04-30T00:00:00Z